Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Articles > Article · 2020
Authors: J Cortes, Dw Cescon, Hs Rugo, Z Nowecki, Sa Im, Mm Yusof, C Gallardo, O Lipatov, Ch Barrios, E Holgado, H Iwata, N Masuda, Mt Otero, Erhan GÖKMEN, S Loi, Z Guo, J Zhao, G Aktan, V Karantza, P Schmid, Investigators. Keynote-355
The Lancet, Journal Indexed in SCI Expanded, International, WoS, 2020, vol 396, pp 1817-1828